Histology-Independent Study of Palbociclib in Patients With Advanced Cancer
Status:
Withdrawn
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The investigational drug being tested in this study is palbociclib. Palbociclib is considered
experimental because it is not approved by the FDA for the treatment of all cancers.
Palbociclib is currently approved for use in breast cancer. Palbociclib is a drug belonging
to a family of drugs called kinase inhibitors. These drugs slow or stop the activity of
particular proteins involved in the growth of human cells and in the abnormal growth of
cancer cells. Blocking these proteins may decrease or stop tumor growth. The purpose of this
study is to assess the safety of the study drug, to see how well it is tolerated, and also to
find a safe dose range of the study drug in patients with specific kinds of tumor genetic
changes.